Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an electrolyte supplement used to prevent or treat hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium replacement in patients receiving diuretics that deplete potassium. * Potassium replacement in patients with significant gastrointestinal losses (e.g., vomiting, diarrhea). ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (1.5 g) once daily. * **Treatment:** 40-100 mEq (3-7.5 g) per day divided into 2-4 doses. Doses should not exceed 20 mEq (1.5 g) per dose. * Maximum daily oral dose: 200 mEq (15 g) unless specific protocol dictates otherwise. * **Intravenous (IV):** * **Treatment of Hypokalemia:** Typically administered as 10-40 mEq (0.75-3 g) per liter of IV fluid. * Maximum infusion rate: Generally 10-20 mEq/hour (0.75-1.5 g/hour) via peripheral line and up to 40 mEq/hour (3 g/hour) via central line. Rates exceeding 10 mEq/hour should be reserved for documented severe hypokalemia and monitored closely. * Maximum concentration: Peripheral lines typically limited to 40 mEq/L (3 g/L); central lines can tolerate higher concentrations (up to 100 mEq/L or 7.5 g/L) but this requires careful administration and monitoring. * **Note:** Exact IV dosing, rate, concentration, and route of administration are highly dependent on the severity of hypokalemia, patient's clinical status, and local hospital protocols. ## Pediatric Dosing * **Oral:** * Dosing is based on body weight and serum potassium levels. A common maintenance dose is 1-2 mEq/kg/day divided into doses, not to exceed 100 mEq (7.5 g) per day. Specific treatment doses may be higher and require close monitoring. * **Intravenous (IV):** * Dosing is typically 0.5-1 mEq/kg/dose (0.0375-0.075 g/dose) added to IV fluids. * Maximum infusion rate: Generally 0.5-1 mEq/kg/hour (0.0375-0.075 g/kg/hour), not to exceed 20 mEq/hour (1.5 g/hour). * Maximum concentration: Generally 40 mEq/L (3 g/L). * **Note:** Pediatric IV potassium administration requires careful calculation and continuous cardiac monitoring, especially for rapid infusions or high doses. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution and significantly reduced doses. Patients with renal impairment are at high risk for hyperkalemia. Dosing should be guided by serum potassium levels and renal function. ## Contraindications * Severe renal impairment. * Conditions where potassium levels may be elevated (e.g., anuria, oliguria, severe burns, adrenal insufficiency, certain medications like ACE inhibitors or ARBs in susceptible individuals). * Hyperkalemia. * Esophageal obstruction, delayed gastric emptying, or conditions that increase the risk of gastrointestinal blockage or perforation (for oral formulations). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain (oral). * **Serious:** * **Hyperkalemia:** The most significant risk. Symptoms include weakness, fatigue, paresthesias, muscle paralysis, cardiac arrhythmias (bradycardia, conduction disturbances, asystole), and cardiac arrest. * Gastrointestinal bleeding, ulceration, perforation, or obstruction (oral formulation, especially with sustained-release products). * Phlebitis, local irritation, pain, or tissue necrosis at IV injection site (IV formulation). ## Key Drug Interactions * **ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Potassium-sparing diuretics (e.g., spironolactone, amiloride), Trimethoprim:** Increase the risk of hyperkalemia. * **NSAIDs:** May reduce the antihypertensive and diuretic effects of potassium supplements and increase the risk of hyperkalemia. * **Anticholinergics:** May increase the risk of gastrointestinal adverse effects with oral potassium supplements. * **Sodium Polystyrene Sulfonate:** Used to treat hyperkalemia; concurrent administration is generally avoided unless specifically indicated to manage concurrent hyperkalemia and hypokalemia. ## Monitoring * **Serum Potassium Levels:** Essential before, during, and after treatment. Frequency depends on dose, route, and clinical status. * **Renal Function (BUN, Creatinine):** Monitor baseline and periodically, especially in patients with known or suspected renal impairment. * **Electrocardiogram (ECG):** Monitor for signs of hyperkalemia (e.g., peaked T waves, widened QRS complex, loss of P waves) particularly with IV administration, rapid infusion, or in patients at high risk. * **Signs and Symptoms of Hypokalemia and Hyperkalemia:** Clinical assessment is crucial. * **Gastrointestinal Symptoms:** For oral formulations, monitor for pain, bleeding, or signs of obstruction. ## Clinical Pearls * Oral potassium chloride should be taken with meals or immediately after to minimize gastrointestinal upset and the risk of esophageal irritation or ulceration. * Sustained-release oral formulations can be difficult to crush or dissolve, potentially leading to incomplete absorption or an increased risk of GI irritation. * Rapid IV infusion of potassium chloride can cause severe pain and phlebitis, and it is a medical emergency if it leads to hyperkalemia and cardiac arrhythmias. * Always dilute IV potassium chloride in a suitable IV fluid and administer via an appropriate infusion device. * Consider the patient's acid-base status, as acidosis can shift potassium out of cells, leading to falsely elevated serum potassium levels. *** *Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines, and exercise your professional judgment when making treatment decisions.*